Post-traumatic stress Disorder (PTSD) is a debilitating mental health condition that affects millions of people worldwide. It affects 5% of the US population,...
MAPS is preparing to submit a formal new drug application to the FDA by end of year The post MAPS Inches Closer to Federal New Drug...
The global inflation surge and monetary policy tightening by major central banks have all contributed to the market volatility this year. Despite that,...
In November 2022, Lusaris Therapeutics made news for its $60 million Series A round. Since then, there has been a curious silence from the company. We...
Silo's SPC-15 was developed in collaboration with Columbia University The post Silo Pharma to test a novel experimental intranasal formulation for PTSD...
The company has plans to become a full-fledged psychedelics manufacturer. The post Optimi Health Gets Permission to Supply MDMA, Psilocybin to Medical...
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the ‘Company’ or ‘Psyched’), a life sciences company focused on the production and...
Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that it...
Leading psychedelic drugs market players include Research Nester are COMPASS Pathways plc, Silo Pharma, Inc., Numinus Wellness Inc., Cybin Inc., Mind Medicine...
MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed...